This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vaccine Enhancement Patch (Pandemic)

Valneva SE

Drug Names(s): Dose-Sparing Adjuvant Patch, Immunostimulant Patch (Pandemic), IS Patch, VEP

Description: The IS patch is used as an adjuvant designed to boost immune responses. After a dose of injected vaccine, the Iomai patch, similar in appearance to a small adhesive bandage, is placed over the vaccination site. There, the adjuvant passes through the skin via specialized cells called Langerhans cells and into the lymph nodes where it works to boost a person's immune response to the vaccine. This approach is known as transcutaneous immunization (TCI). This would have the effect of expanding limited vaccine supplies by allowing public health officials to use fewer or lower doses of vaccine. The patch formulations are stable at room temperature.

Deal Structure: In August 2008, Intercell AG announced the completion of the acquisition of Iomai.

In December 2009, Intercell and GlaxoSmithKline Biologicals (GSK) announced an agreement to form a strategic alliance to accelerate the development and commercialization of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travelers' diarrhea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio.

Under the terms of the agreement, GSK will make an up-front cash contribution of EUR 33.6 (USD 49.4) million, in addition to an equity investment of up to EUR 84 (USD 123.5) million through a staggered shareholding purchase option of up to 5 % in Intercell.

In May 2013, Valneva announced its creation through the completion of the merger of equals between Vivalis and Intercell.

Partners: GlaxoSmithKline plc


Vaccine Enhancement Patch (Pandemic) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug